<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038608</url>
  </required_header>
  <id_info>
    <org_study_id>2012.722</org_study_id>
    <nct_id>NCT02038608</nct_id>
  </id_info>
  <brief_title>Compensatory Mechanisms in Parkinson Disease (PD)</brief_title>
  <acronym>CompensationPD</acronym>
  <official_title>Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease is characterized by a large number of non motor, especially&#xD;
      neuropsychiatric, signs. Their pathophysiology is complex but the role of dopaminergic and&#xD;
      serotoninergic systems dysfunction is suggested by several studies. In addition, the&#xD;
      serotoninergic system is involved in the pathophysiology of dyskinesias. Very few studies&#xD;
      have analyzed the abnormalities of these two neurotransmission systems at disease onset, in&#xD;
      de novo PD patients. Furthermore, the parallel evolution of the degeneration of the&#xD;
      dopaminergic and serotoninergic systems with disease progression remains unknown. Thus the&#xD;
      present study aims at determining, by using PET and 11C-PE2I and 11C-DASB the respective role&#xD;
      of the serotoninergic and dopaminergic systems dysfunction in motor and non motor&#xD;
      manifestations in PD, at different evolution stages.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respective progression of both dopaminergic and serotoninergic lesions in Parkinson's disease</measure>
    <time_frame>This will be achieved at the end of the inclusion period, thus 24 to 36 months after study onset (January 2014).</time_frame>
    <description>Dopaminergic lesions will be determined by positron emission tomography (PET) using 11C-PE2I in 3 groups of PD patients (de novo; mid-stage (4-7 years of evolution); late-stage (8-10 years of evolution). Serotoninergic lesions will be assessed by positron emission tomography (PET) using 11C-DASB in the same 3 groups of PD patients. In addition a control group will be included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations between neuropsychiatric observed in Parkinson's disease at different stages of evolution</measure>
    <time_frame>These correlations will be determined at the end of the inclusion period, thus 24 to 36 months after study onset (January 2014).</time_frame>
    <description>Dopaminergic lesions will be determined by positron emission tomography (PET) using 11C-PE2I in 3 groups of PD patients (de novo; mid-stage (4-7 years of evolution); late-stage (8-10 years of evolution). Serotoninergic lesions will be assessed by positron emission tomography (PET) using 11C-DASB in the same 3 groups of PD patients. In addition a control group will be included.&#xD;
The neuropsychiatric manifestations studied are :&#xD;
hypo and hyperdopaminergic signs : ECMP scale&#xD;
Apathy using LARS scale&#xD;
Anxiety using BAI scale&#xD;
Depression using BDI scale (Beck Depression Inventory)&#xD;
Affective well-being and asthenia using visual analogic scales of Norris&#xD;
MATHYS scale&#xD;
Global cognitive scale : MATTIS&#xD;
Food behavior using TFEQ scale&#xD;
Personality : TCI-R scale&#xD;
Impulsivity by UPPS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of dopaminergic and serotoninergic lesions in fatigue</measure>
    <time_frame>This will be determined at the end of the inclusion period, thus 24 to 36 months after study onset (January 2014).</time_frame>
    <description>: Dopaminergic lesions will be determined by positron emission tomography (PET) using 11C-PE2I in 3 groups of PD patients (de novo; mid-stage (4-7 years of evolution); late-stage (8-10 years of evolution). Serotoninergic lesions will be assessed by positron emission tomography (PET) using 11C-DASB in the same 3 groups of PD patients. In addition a control group will be included.&#xD;
Fatigue will be assessed using the PDFS-16 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between the severity of dopaminergic and serotoninergic lesions and the quality of life</measure>
    <time_frame>These correlations will be determined at the end of the inclusion period, thus 24 to 36 months after study onset (January 2014).</time_frame>
    <description>Dopaminergic lesions will be determined by positron emission tomography (PET) using 11C-PE2I in 3 groups of PD patients (de novo; mid-stage (4-7 years of evolution); late-stage (8-10 years of evolution). Serotoninergic lesions will be assessed by positron emission tomography (PET) using 11C-DASB in the same 3 groups of PD patients. In addition a control group will be included.&#xD;
Fatigue will be assessed using the PDQ39 (Parkinson's Disease Questionnaire) scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET</intervention_name>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Patients presenting doparesponsive Parkinson's disease&#xD;
&#xD;
          -  Patient's age between 40 and 70 years old&#xD;
&#xD;
          -  Absence of other neurological or psychiatric disease&#xD;
&#xD;
          -  Absence of cognitive decline ( MATTIS &gt; 130)&#xD;
&#xD;
          -  For women of childbearing age a pregnancy test and a contraceptive method will be&#xD;
             required&#xD;
&#xD;
          -  Informed consent sign&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  subject's age between 40 and 70 years old&#xD;
&#xD;
          -  Absence of neurological or psychiatric disease&#xD;
&#xD;
          -  Absence of cognitive decline ( MATTIS &gt; 130)&#xD;
&#xD;
          -  For women of childbearing age a pregnancy test and a contraceptive method will be&#xD;
             required&#xD;
&#xD;
          -  Informed consent sign&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  patient's age &lt; 40 years old or &gt; 70 years old&#xD;
&#xD;
          -  Other neurological or psychiatric disease&#xD;
&#xD;
          -  Cognitive decline (MATTIS &lt; 130).&#xD;
&#xD;
          -  Having participated to a PET or SPECT study in the last 12 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe concomitant disease&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  subject's age &lt; 40 years old or &gt; 70 years old&#xD;
&#xD;
          -  Neurological or psychiatric disease&#xD;
&#xD;
          -  Cognitive decline (MATTIS &lt; 130).&#xD;
&#xD;
          -  Having participated to a PET or SPECT study in the last 12 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe concomitant disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>serotonin</keyword>
  <keyword>dopamine</keyword>
  <keyword>non motor</keyword>
  <keyword>progression</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

